Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 6 of the 55 sources its claims cite were checked for support.
Abstract
Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed to replicate the efficacy of injectable GLP-1 RAs for glycemic control and weight reduction while improving convenience and adherence. Preclinical studies have demonstrated potent receptor engagement, favorable pharmacokinetics, and central nervous system activity. Phase 1–3 clinical trials have shown significant reductions in glycated hemoglobin (HbA1c), fasting and postprandial glucose, body weight, and cardiovascular risk biomarkers, with an acceptable safety profile. This comprehensive review integrates pharmacological, clinical, and mechanistic evidence, critically evaluates the data, identifies knowledge gaps, and outlines future directions for orforglipron in the treatment of type 2 diabetes and obesity.
Overview
CoChat Summary
TL;DR
Orforglipron is an oral, nonpeptide, allosteric GLP-1 receptor agonist that produces clinically meaningful HbA1c and weight reductions in type 2 diabetes and obesity, with a safety profile dominated by dose-dependent gastrointestinal events. This comprehensive review integrates preclinical, Phase 1–3, mechanistic, and meta-analytic evidence while highlighting unresolved questions about long-term outcomes, comparative effectiveness, and understudied populations.
Key findings
- Orforglipron is orally bioavailable (~30–40%), reaches peak plasma concentrations within 2–4 h, and supports once-daily dosing; food intake has minimal impact on exposure.
- In Phase 2 T2D trials, once-daily orforglipron produced dose-dependent HbA1c reductions exceeding 1.5 percentage points at 26 weeks and mean body weight reductions of 7–10% at 26 weeks.
- In ACHIEVE-1, early T2D patients had mean absolute HbA1c reductions of ~1.4–1.6% over 40 weeks without significant hypoglycemia; in ATTAIN, over 72 weeks, the highest dose yielded mean weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations.
- Meta-analyses cited in the review report pooled weight reductions of 9–12% versus placebo at 26–72 weeks and weighted mean HbA1c reductions of 1.3–1.6% versus placebo; gastrointestinal adverse events were the most common, while hypoglycemia was rare and no pancreatitis, retinal detachment, or ischemic optic neuropathy signals were observed.
Methods
- Design: comprehensive narrative review integrating preclinical pharmacology, Phase 1–3 clinical trials, mechanistic substudies, and published meta-analyses; no new primary data are reported.
- Data/sample: healthy volunteers, participants with T2D, participants with obesity with or without diabetes, Japanese participants with T2D, and trial populations from ACHIEVE-1 and ATTAIN-1/ATTAIN-2.
- Main analysis: qualitative synthesis of pharmacokinetic, pharmacodynamic, glycemic, weight-loss, safety, cardiovascular biomarker, hepatic, and renal data, with summary tables and cross-trial comparisons.
Limitations
- Stated in the paper: most trials lasted only ~26–72 weeks, limiting assessment of long-term durability, late-emerging adverse events, and sustained cardiometabolic benefit; elderly patients, adolescents, individuals with severe obesity, and those with advanced renal or hepatic impairment were excluded or minimally represented; real-world effectiveness data are lacking; direct head-to-head comparisons and hard cardiovascular/renal outcome trials are absent.
- Stated in the paper: mechanistic gaps remain, including the relative contributions of weight-dependent versus weight-independent glycemic effects, central appetite pathways, β-cell preservation, and the molecular basis of nonpeptide allosteric activation.
- Evident from the text: as a narrative review, conclusions rely on cross-trial comparisons and surrogate biomarkers rather than primary comparative or long-term outcome data; no systematic search or formal quality appraisal is described.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
1 Valid · 2 Not valid · 27 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In adults with T2D, participants receiving the higher dose regimens achieved mean body weight reductions of 7–10% at 26 weeks, with progressive weight loss observed over the study period [29].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.1. Phase 2 Evidence
What the sources say
- Disputedcites [29] Pratt, 2023, Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
Our copy is a Phase 1b study of only 12 weeks' duration: the Abstract reports body weight change of -0.24 to -5.8 kg across orforglipron doses versus 0.5 kg with placebo at Week 12, and the Discussion/Figure 3 give LSM differences of approximately -4 to -6 kg versus placebo at Week 12 — no percentage-based weight loss and no 26-week timepoint anywhere. Decisively, the Discussion states that 'two Phase 2 trials are currently ongoing in patients with T2D (NCT05048719) and in patients with obesity (NCT05051579)', i.e. this paper reports no Phase 2 results at all, and it explicitly notes its own small sample size and short exposure as limitations requiring larger, longer trials. Thus the attributed finding (7-10% mean body weight reduction at 26 weeks in Phase 2, higher dose regimens) is contrary to what this source says; the only 'progressive weight loss' it supports is over Day 7 to Week 12. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
None of the sources cited for this claim have been checked yet.
In the paper
“Notably, a substantial proportion of participants achieved ≥10% weight loss, a threshold associated with meaningful metabolic improvements and cardiovascular risk reduction.”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.2. ATTAIN Trials
What the sources say
- Not checked yetcites [25] Wharton, 2023, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity, N. Engl. J. Med. source
- Not checked yetcites [30] Horn, 2026, Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): A phase 3, double-blind, randomised, multicentre, placebo-controlled trial, Lancet source
- Not checked yetcites [46] Wharton, 2025, Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment, N. Engl. J. Med. source
- Could not verifycites [47] Wharton, 2025, Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes, Cardiovasc. Diabetol. sourceExperimental — accuracy not yet measured
The Introduction reports average weight loss in two Phase 2 orforglipron studies, and Methods identifies those studies by trial registration number (pages unavailable). Neither passage identifies an ATTAIN trial or reports the proportion of participants who lost at least 10% of their weight; searches for ATTAIN and the 10% responder threshold found no such passage in our copy. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Meta-analyses of randomized controlled trials corroborate these findings, demonstrating pooled weight reductions of 9–12% relative to placebo at 26–72 weeks [49,50].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.3. Comparative Context
What the sources say
- Partly supportedcites [49] Dutta, 2024, Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis, Obes. Sci. Pract. sourceExperimental — accuracy not yet measured
Dutta et al. (2024) is indeed a systematic review and meta-analysis of orforglipron RCTs, and it does report placebo-corrected percent weight reductions, so the general point holds. But the magnitudes and time frame are not what the paper shows: its pooled (meta-analytic) reductions vs placebo at 26 weeks are MD −5.48% (12 mg), −8.51% (24 mg), −8.84% (36 mg) and −8.24% (45 mg) (RESULTS, Effect on body weight and body mass index), i.e. ~5.5–8.8%, not 9–12%; the only 9–12%-range figures are the 7.1%–12.3% placebo-corrected changes reported narratively by one included trial (Wharton 2023) at week 36, not a pooled estimate. The 72-week endpoint is unsupported: the Abstract (Results) states data from three RCTs in 774 people with follow-up duration of up to 36 weeks, and no passage in our copy reports 72-week outcomes. (LLM, conf=0.80)
- Partly supportedcites [50] Lutkemeyer, 2024, Effects of once-daily oral orforglipron on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials, Arch. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
Our copy is indeed a systematic review/meta-analysis of four RCTs (815 patients) reporting greater weight reduction with orforglipron versus placebo, but its pooled percentage figure is WMD -8.01% (95% CI -12.51 to -3.52%; two trials, 605 participants) and its absolute figure -6.14 kg (four trials, 733 participants) — below the claimed 9–12% point range. The duration qualifier is also unsupported: Table 1 (Study selection and characteristics) lists follow-ups of 4, 12 and 26 weeks only, and the Discussion states the included phase 1 and 2 RCTs 'had short follow-ups' with no plateau reached, so nothing here covers 26–72 weeks. Thus the direction and existence of a pooled placebo-relative effect are supported, while the 9–12% magnitude and the up-to-72-week timeframe attributed to this source are not. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Importantly, the absence of clinically relevant hepatic or renal toxicity suggests that no dose adjustment is required in patients with mild to moderate hepatic or renal dysfunction, a practical advantage in routine clinical practice [34].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 5. Safety, Tolerability, and Cardiovascular Biomarkers > 5.3. Hepatic and Renal Safety
What the sources say
- Could not verifycites [34] Gogineni, 2024, Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: Where are we now?, Expert Opin. Pharmacother. sourceExperimental — accuracy not yet measured
Our copy's Orforglipron section and Table 3 report only HbA1c/weight/BP efficacy and a gastrointestinal-predominant AE profile (12-19% discontinuation), with no statement about hepatic or renal toxicity and no statement about dose adjustment in mild to moderate hepatic or renal impairment (searched: 'dose adjustment', 'hepatic/renal impairment', 'orforglipron liver kidney'). The nearest dosing statement — that orforglipron 'has minimal dosing requirements (i.e it does not require to be taken on an empty stomach)' (Orforglipron, p. n/a) and 'less burdensome administration' in 'The future of oral GLP-1 RAs' — concerns food/water restrictions, not organ dysfunction, so it does not carry the attributed point. The only hepatic-toxicity content in our copy is about a different molecule, lotiglipron ('elevated transaminases and concerns regarding potential liver toxicity', Other oral GLP-1 RAs not progressed to phase 3 trials), which neither supports nor contradicts the claim. (LLM, conf=0.68)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
In the paper
“Improvements were consistent across baseline HbA1c, BMI, sex, and age subgroups, indicating broad applicability.”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 3. Glycemic Efficacy > 3.3. Phase 3 Evidence
What the sources say
- Not checked yetcites [27] Rosenstock, 2025, Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
27 more claims
Create a free account to see all 55 claims and to verify the 49 references still open.
- It may state two separate claims as one. 22
- The quote only partly states this claim. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently approved or emerging daily oral small-molecule GLP-1 agonists, such as orforglipron, may improve access and reduce injection burden [88].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 5. Safety, Tolerability, and Cardiovascular Biomarkers > 5.3. Hepatic and Renal Safety
“Detailed disposition analyses demonstrate that the compound undergoes limited hepatic metabolism and does not rely heavily on cytochrome P450–mediated pathways”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 5. Safety, Tolerability, and Cardiovascular Biomarkers > 5.3. Hepatic and Renal Safety
“Indeed, orforglipron is eliminated predominantly through hepatic metabolism, with Phase I oxidative biotransformation as the principal clearance mechanism. CYP-mediated metabolism (primarily involving CYP3A) is responsible for most systemic clearance”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > 4. Weight Loss and Obesity Outcomes > 4.1. Phase 2 Evidence
“In adults with T2D, participants receiving the higher dose regimens achieved mean body weight reductions of 7–10% at 26 weeks, with progressive weight loss observed over the study period [29].”
§ Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes > References
“29. Pratt E. Ma X. Liu R. Robins D. Coskun T. Sloop K.W. Haupt A. Benson C. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes”
Citations
Cites
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161521 · Cited by 799
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478 · cited 2×
“Across both trials, orforglipron produced significant, sustained weight reductions over 72 weeks, with the highest dose yielding mean body weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations [25,30,46,47].”
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
Kawai, T., Sun, B., Yoshino, H., Feng, D., Suzuki, Y., Fukazawa, M., Nagao, S., Wainscott, D. B., Showalter, A. D., Droz, B. A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014879117 · Cited by 231 · cited 4×
“While structural studies have provided important insights into binding topology and receptor conformational changes [30,32,33,36–39], the extent to which different allosteric ligands induce biased signaling or differential receptor trafficking is not fully resolved.”
InfluentialOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511774 · Cited by 189
Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01302-8 · Cited by 184 · cited 2×
“Once-daily orforglipron produced significant, dose-dependent reductions in HbA1c, with higher doses achieving reductions exceeding 1.5 percentage points at 26 weeks [26].”
InfluentialEfficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists
Galli, M., Benenati, S., Laudani, C., Simeone, B., Sarto, G., Ortega‐Paz, L., Rocco, E., Bernardi, M., Spadafora, L., D’Amario, D., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.027 · Cited by 140
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Knop, F. K., Vilsbøll, T., Larsen, S., Højberg, P. V., Vølund, A., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00059.2006 · Cited by 120
Emerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102 · cited 1×
“When evaluated in the context of established injectable GLP-1 RAs, orforglipron exhibits a broadly comparable safety and tolerability profile, with gastrointestinal adverse events constituting the most frequent treatment-emergent effects [70–73].”
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99
Ayoub, M., Chela, H. K., Amin, N. A., Hunter, R., Anwar, J., Tahan, V., & Daglilar, E. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030944 · Cited by 94
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor
Cong, Z., Chen, L.-N., Ma, H., Zhou, Q., Zou, X., Ye, C., Dai, A., Liu, Q., Huang, W., Sun, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24058-z · Cited by 89
Horn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
Karakasis, P., Patoulias, D., Pamporis, K., Stachteas, P., Bougioukas, K. I., Klisic, A., Fragakis, N., & Rizzo, M. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155710 · Cited by 66
Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T., Sloop, K. W., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15184 · Cited by 62 · cited 1×
“Orforglipron (LY3502970) is a synthetic, orally bioavailable, nonpeptide agonist of the GLP-1 receptor that was rationally designed to overcome the intrinsic limitations of peptide-based GLP-1 RAs, particularly poor oral bioavailability and rapid enzymatic degradation [28,29,32,33].”
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60 · cited 2×
“Orforglipron (LY3502970) is a synthetic, orally bioavailable, nonpeptide agonist of the GLP-1 receptor that was rationally designed to overcome the intrinsic limitations of peptide-based GLP-1 RAs, particularly poor oral bioavailability and rapid enzymatic degradation [28,29,32,33].”
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 54
Xie, Z., Zheng, G., Liang, Z., Li, M., Deng, W., & Cao, W. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156038 · Cited by 54 · cited 1×
“Early mechanistic and clinical studies suggest additive or synergistic effects on glycemic control and weight loss when GLP-1 receptor agonists are combined with SGLT2 inhibition, without a proportional increase in hypoglycemia risk [85,99,100].”
Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis
Nong, K., Jeppesen, B. T., Shi, Q., Agoritsas, T., Guyatt, G. H., White, H., Gao, Y., Agarwal, A., Macdonald, H., Zou, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083039 · Cited by 53
Wen, J., Nadora, D., Bernstein, E., How-Volkman, C., Truong, A., Joy, B., Kou, M., Muttalib, Z., Alam, A., & Frezza, E. E. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70113 · Cited by 53
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
Sloop, K. W., Cox, A. L., Wainscott, D. B., White, A., Droz, B. A., Stutsman, C., Showalter, A. D., Suter, T. M., Dunbar, J. D., Snider, B. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp5765 · Cited by 52 · cited 2×
“This binding site partially overlaps with the orthosteric peptide pocket but extends into a distinct transmembrane sub-pocket, a feature thought to underlie the G s -biased signaling profile of orforglipron compared with other GLP-1R agonists [40].”
Guo, H., Guo, Q., Li, Z., & Wang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1461398 · Cited by 49
Incretin-based therapies for the treatment of obesity-related diseases
Caruso, I., Cignarelli, A., Sorice, G. P., Perrini, S., & Giorgino, F. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00030-5 · Cited by 48
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 42
Ryder, R. E. J. (2013) · Diabetic Medicine · doi:10.1111/dme.12301 · Cited by 41
Cong, Z., Zhou, Q., Li, Y., Chen, L.-N., Zhang, Z.-C., Liang, A., Liu, Q., Wu, X., Dai, A., Xia, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200155119 · Cited by 41
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Alsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 39
Lomeli, L. D., Kodali, A. M., Tsushima, Y., Mehta, A., & Pantalone, K. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111806 · Cited by 39
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01554-1 · Cited by 38 · cited 2×
“These findings were subsequently corroborated in Phase 1b and Phase 2 studies enrolling participants with T2D, in whom baseline hepatic enzyme abnormalities are common due to metabolic liver disease [42,68].”
Li, H., Yu, G., Huang, Q., Yang, B., Nie, J., Liu, Y., & Tu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116150 · Cited by 38
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35 · cited 1×
“…no clinically meaningful elevations in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin were observed following single or multiple ascending doses of orforglipron, indicating an absence of acute hepatocellular or cholestatic toxicity [41,63,67].”
Dutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
GLP-1 based agents and acute pancreatitis
Gale, E. A. M. (2013) · BMJ · doi:10.1136/bmj.f1263 · Cited by 33
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
Kong, F., Zhao, Y., Zhang, W., Wang, X., Wu, T., Zhou, Z., Xu, Y., Xia, L., & Sun, T. (2026) · Nature Communications · doi:10.1038/s41467-025-67701-9 · Cited by 29
Tang, H., Lu, Y., Zhang, B., Zhou, T., Zhang, D., Chen, J., Chen, Y., Asch, D. A., & Chen, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70054 · Cited by 28
Wharton, S., Rosenstock, J., Konige, M., Lin, Y., Duffin, K., Wilson, J., Banerjee, H., Pirro, V., Kazda, C., & Mather, K. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02781-x · Cited by 26
An, X., Sun, W., Wen, Z., Duan, L., Zhang, Y., Kang, X., Ji, H., Sun, Y., Jiang, L., Zhao, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16228 · Cited by 25
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds
Cohen, D. (2013) · BMJ · doi:10.1136/bmj.f2607 · Cited by 24
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Liao, H.-J., & Tzen, J. T. C. (2022) · Metabolites · doi:10.3390/metabo12060549 · Cited by 21 · cited 1×
“…a substrate for proteolytic enzymes such as dipeptidyl peptidase-4, enabling efficient absorption from the gastrointestinal tract after oral administration and eliminating the need for absorption enhancers or complex formulation strategies that are required for oral peptide GLP-1 therapies [33–35].”
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis
Nogueira, A., Rassi, T. N. D. O., Iqbal, A., Felix, N. S., Alghaith, O. A. H. A., Khan, A., Rassi, N., Maia, M., & Moura, F. A. (2026) · Diabetes Care · doi:10.2337/dc25-1238 · Cited by 18
Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective
Sidik, S. (2023) · Nature · doi:10.1038/d41586-023-02092-9 · Cited by 18 · cited 1×
“So, available evidence indicates that orforglipron achieves a safety profile that is at least comparable to injectable GLP-1 RAs while offering additional advantages related to route of administration and lack of immunogenicity [47,84,85].”
Nauck, M. A., & Horowitz, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01201-1 · Cited by 16 · cited 4×
“Editorial analyses emphasize that this nonpeptide oral agent challenges the paradigm that oral therapies cannot replicate injectable GLP-1 RA efficacy [39].”
InfluentialArow, Z., Hornik‐Lurie, T., Hilu, R., Giladi, E., Arnson, Y., Assa, H. V., Assali, A. R., & Pereg, D. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02874-7 · Cited by 16
Shuja, S. H., Shuja, M. H., Shaukat, A., Hannat, R., Ahmed, I., Adam, S., Abdelkhalek, A., Changez, M. I. K., Ullah, I., Ahmed, R., et al. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.09.039 · Cited by 16
Mahadevan, A., Vosooghi, A., Arora, J. S., Kumar, R. S., Singh, G., Tsai, K. K., & Quandt, Z. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf703 · Cited by 16
Takrori, E., Peshin, S., & Singal, S. (2025) · Medicina · doi:10.3390/medicina61111987 · Cited by 13
Krishnan, S., Srivastava, P. K., Attaluri, J., Nayeri, R., Chatterjee, D., Patel, J., Nsair, A., Budoff, M. J., & Nayeri, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12010019 · Cited by 13
Rosenstock, J., Robins, D. A., Duffin, K. L., Wilson, J. M., Lin, Y., Banerjee, H., Eyde, S., KAZDA, C. M., Кониг, М., & Mather, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70022 · Cited by 13
From needles to pills: oral GLP-1 therapy enters the obesity arena
Santulli, G. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00245-5 · Cited by 12
Self-citationAdvancements in the management of obesity: a review of current evidence and emerging therapies
Abdalla, M. A., Ssemmondo, E., Mark‐Wagstaff, C., & Sathyapalan, T. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2347258 · Cited by 10
Zhang, S., Yu, B., Xu, J., Jin, S., Li, Y., Bing, H., Li, J., Ma, X., Zhang, X., & Zhao, L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0533 · Cited by 10
Lütkemeyer, C., Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Petris, I., Santos, H. V. D., Wille, J. M., Hohl, A., Ronsoni, M. F., & Sande-Lee, S. V. D. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0469 · Cited by 10 · cited 1×
“Meta-analyses of randomized controlled trials corroborate these findings, demonstrating pooled weight reductions of 9–12% relative to placebo at 26–72 weeks [49,50].”
Šedová, P., Vrablík, M., Kala, P., Ošťádal, P., Tichopád, A., Tomek, A., Mikulík, R., Donin, G., Littnerová, S., Kent, J. A., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag002 · Cited by 9
Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare
Bhat, S., Fernandez, C. J., Lakshmi, V., & Pappachan, J. M. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i8.107991 · Cited by 9
Pandey, R. K., Jan, M., Mohammad, A., Jawaid, K. A., Naveed, M., Abid, M. A., Amir, A. B., Ahmed, S., Safiullah, M., Bhatti, M. I., et al. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70134 · Cited by 9
Salama, L., & Sinn, L. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf053 · Cited by 9
Sørensen, K. K., Yazdanfard, P. D. W., Zareini, B., Pedersen‐Bjergaard, U., Kosjerina, V., Andersen, M. P., Munch, A., Ohlendorff, J. S., Schmid, S., Lanzinger, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02915-1 · Cited by 9
Tong, J., Li, N., Hu, F., & Yue, Y. (2025) · Diabetes Care · doi:10.2337/dc25-1822 · Cited by 9
Raza, S. S., Zakir, Z., Hashmat, A., Awan, S. K., & Varrassi, G. (2025) · Cureus · doi:10.7759/cureus.96739 · Cited by 8
Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 7
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 7
Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity
Chow, E. W.-K., & Chow, E. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02381-5 · Cited by 7
Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
Morse, B. L., Bhattachar, S., Ma, X., Coutant, D. E., Czeskis, B., Nicoll, C., & Cassidy, K. C. (2026) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1594 · Cited by 7 · cited 5×
“…no clinically meaningful elevations in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, or total bilirubin were observed following single or multiple ascending doses of orforglipron, indicating an absence of acute hepatocellular or cholestatic toxicity [41,63,67].”
InfluentialZhang, X., Chi, R., Xu, J., Meng, C., Wang, Z., Ruo, W., Xin, F., Xu, T., Guo, F., Wang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.116010 · Cited by 7
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Ohwaki, K., Nakamura, C., Nasu, R., Takenouchi, K., & Hirase, T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70157 · Cited by 5
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000046671 · Cited by 5 · cited 2×
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a cornerstone in the management of T2D and obesity, providing glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, appetite reduction, and cardiometabolic benefits [17–23].”
Al‐Horani, R. A., Aliter, K. F., & Aliter, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276832231124170324 · Cited by 5
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Pourkarim, F., & Entezari‐Maleki, T. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2311840 · Cited by 5
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Vernaza-Trujillo, D.-A., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663787 · Cited by 5
Orforglipron in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2594493 · Cited by 4
GLP‐1 receptor agonists and reduced dementia risk: Real‐world evidence stacks up
Lam, Y. W., Fajkić, A., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70451 · Cited by 4
Oral GLP-1 Receptor Agonists for Weight Loss
Krinsky, D., Marcucci, A., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000833 · Cited by 4
Zhou, J., Wang, F., & Li, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646956 · Cited by 3 · cited 2×
“So, available evidence indicates that orforglipron achieves a safety profile that is at least comparable to injectable GLP-1 RAs while offering additional advantages related to route of administration and lack of immunogenicity [47,84,85].”
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3 · cited 1×
“Mechanistic substudies suggest that orforglipron engages central appetite pathways similarly to peptide GLP-1 RAs, contributing to reductions in caloric intake and body weight independent of glucose lowering [44].”
Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease
Chi, K., Pollanen, S., Hu, J., Lee, P., Mangalesh, S., Ezenna, C. G., Joseph, M., Krishna, M. M., Lin, Y.-S., Acero, L. M. R., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf104 · Cited by 3
Coleman, R. L., Adler, A., Mentz, R. J., Fudim, M., Sattar, N. A., & Holman, R. R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02866-7 · Cited by 3
Akcan, T., KINGMAN, R. S., Morgan, M., LIU, Y.-T., Kingston, K., & Lal, R. (2026) · Diabetes Care · doi:10.2337/dc25-2569 · Cited by 3
Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
(2025) · New England Journal of Medicine · doi:10.1056/nejmc2515117 · Cited by 2
In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk
Lau, D. (2023) · Annals of Internal Medicine · doi:10.7326/j23-0077 · Cited by 2
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and acute pancreatitis
Whitcomb, D. C. (2025) · Pancreatology · doi:10.1016/j.pan.2025.07.005 · Cited by 2
Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?
Seetharaman, R., & Pandit, S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0234 · Cited by 2
Chen, S., Lobato, C. B., Wong, C., Manchanda, Y., Viloria, K., Davies, I., Andersen, D. B., Ast, J., Sloop, K. W., Hodson, D. J., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102304 · Cited by 2
Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?
Seetharaman, R., & Pandit, S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0172 · Cited by 1 · cited 1×
“As a nonpeptide small molecule, orforglipron does not elicit an immune response, thereby eliminating the risk of antibody formation and representing a theoretical and practical safety advantage over peptide therapies [81–83].”
One small molecule for man, one giant leap for mankind with obesity
Novikoff, A., & Müller, T. D. (2025) · Med · doi:10.1016/j.medj.2025.100924 · Cited by 1
Margoni, A., & Papavassiliou, A. G. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108060 · Cited by 1
GLP-1 receptor agonism counteracts omics aging in mice
Kriebs, A. (2026) · Nature Aging · doi:10.1038/s43587-025-01063-1 · Cited by 1
Research works printed but not linked: 3
- Jagarlapudi, 2025, Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med., 393, 2276, 10.1056/nejmc2515117 · DOI · Paper page
- Nagaoka, 2025, Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med., 393, 2276, 10.1056/nejmc2515117 · DOI · Paper page
- Xie, 2025, Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med., 393, 2276, 10.1056/nejmc2515117 · DOI · Paper page
Cited by
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
Li, Y., Glotfelty, E. J., Parekh, P., Batsaikhan, B., Luo, W., Jackson, S. N., Harvey, B. K., & Greig, N. H. (2026) · Cells · doi:10.3390/cells15141301 · Cited by 2
Daily Glucagon-like Peptide-1 Receptor Agonists in Type 1 Diabetes
Innes, R., Petrie, J. R., & Dejgaard, T. F. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.002
Metadata
- Authors
- Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G.
- Affiliations
- City University of New York (US)
- Casa di Cura “Clinica Montevergine”, 83013 Mercogliano, Italy
- Corresponding author
- Santulli, Gaetano
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-01-30
- Volume
- 27
- Issue
- 3
- Pages
- 1409
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12898445
- OpenAlex
- W7126191026
- Cited by
- 22
- References
- 91
- Citations by year
- 2026: 22
- FWCI
- 23.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (R01-HL146691, R01-HL164772, R01-HL159062)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK123259, R01-DK033823)
- American Heart Association (24IPA1268813)
- AHA (AHA-23POST1026190, AHA-21POST836407, 26POST1563063, AHAPOST22915561, AHAPOST241195524)
- NIH (T32-HL-172255)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- orforglipron, GLP-1 receptor agonists, oral GLP-1 receptor agonists, type 2 diabetes, obesity, glycemic control, weight loss, HbA1c, cardiovascular risk markers, pharmacokinetics, drug safety
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Oxadiazoles, Fluorine Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.